Keywords: Bayer, Regeneron, Wet AMD, Lucentis, VEGF Trap-Eye, Aflibercept, Regulatory filing, Phase III studies

Ph III studies show Bayer and Regeneron VEGF Trap-Eye in wet AMD meets primary endpoints versus Lucentis

Article | 22 November 2010

Print This

German drug major Bayer (BAY: DE) and US partner Regeneron Pharmaceuticals (Nasdaq: REGN) reveal that, in two parallel Phase III ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in